These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15389124)

  • 1. No effect of the prothrombin G20210A mutation on protein C activation in a large kindred with type I protein C deficiency.
    Vossen CY; Strandberg K; Stenflo J; Rosendaal FR; Callas PW; Long GL; Bovill EG
    Blood Coagul Fibrinolysis; 2004 Oct; 15(7):573-6. PubMed ID: 15389124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred.
    Bovill EG; Hasstedt SJ; Callas PW; Valliere JE; Scott BT; Bauer KA; Long GL
    Thromb Haemost; 2000 Mar; 83(3):366-70. PubMed ID: 10744139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family.
    Vossen CY; Hasstedt SJ; Rosendaal FR; Callas PW; Bauer KA; Broze GJ; Hoogendoorn H; Long GL; Scott BT; Bovill EG
    J Thromb Haemost; 2004 Feb; 2(2):242-7. PubMed ID: 14995985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia.
    Castoldi E; Simioni P; Tormene D; Thomassen MC; Spiezia L; Gavasso S; Rosing J
    J Thromb Haemost; 2007 May; 5(5):971-9. PubMed ID: 17461930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprothrombinaemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis.
    Binetti BM; Rotunno C; Tripodi A; Asti D; Semeraro F; Semeraro N; Colucci M
    Thromb Haemost; 2006 Apr; 95(4):606-11. PubMed ID: 16601829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk.
    Vayá A; Mira Y; Mateo J; Falco C; Villa P; Estelles A; Corella D; Fontcuberta J; Aznar J
    Thromb Haemost; 2003 Mar; 89(3):452-7. PubMed ID: 12624627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis.
    Castaman G; Tosetto A; Simioni M; Ruggeri M; Madeo D; Rodeghiero F
    Thromb Haemost; 2001 Sep; 86(3):804-8. PubMed ID: 11583311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and/or soluble thrombomodulin antigen and activity.
    Strandberg K; Svensson PJ; Ohlin AK
    Thromb Res; 2007; 121(2):145-51. PubMed ID: 17499343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation.
    Brummel-Ziedins KE; Orfeo T; Callas PW; Gissel M; Mann KG; Bovill EG
    PLoS One; 2012; 7(9):e44378. PubMed ID: 22984498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation.
    Koenen RR; Tans G; van Oerle R; Hamulyák K; Rosing J; Hackeng TM
    Blood; 2003 Sep; 102(5):1686-92. PubMed ID: 12730108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial thrombophilia is an oligogenetic disease: involvement of the prothrombin G20210A, PROC and PROS gene mutations.
    Boinot C; Borgel D; Kitzis A; Guicheteau M; Aiach M; Alhenc-Gelas M
    Blood Coagul Fibrinolysis; 2003 Feb; 14(2):191-6. PubMed ID: 12632031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of activated protein C-protein C inhibitor complex in patients with hypercoagulable states.
    Watanabe R; Wada H; Sakakura M; Mori Y; Nakasaki T; Okugawa Y; Gabazza EC; Hayashi T; Nishioka J; Suzuki K; Shiku H; Nobori T
    Am J Hematol; 2000 Sep; 65(1):35-40. PubMed ID: 10936861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene.
    Kyrle PA; Mannhalter C; Béguin S; Stümpflen A; Hirschl M; Weltermann A; Stain M; Brenner B; Speiser W; Pabinger I; Lechner K; Eichinger S
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1287-91. PubMed ID: 9714136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency.
    Hézard N; Bouaziz-Borgi L; Remy MG; Nguyen P
    Clin Chem; 2006 Apr; 52(4):665-70. PubMed ID: 16469858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prothrombin activity and concentration in healthy subjects with and without the prothrombin G20210A mutation.
    von Ahsen N; Lewczuk P; Schütz E; Oellerich M; Ehrenreich H
    Thromb Res; 2000 Sep; 99(6):549-56. PubMed ID: 10974339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.
    Simioni P; Scarano L; Gavasso S; Sardella C; Girolami B; Scudeller A; Girolami A
    Br J Haematol; 1996 Feb; 92(2):435-41. PubMed ID: 8603014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coagulation activation and ultrasound characteristics in patients with carotid artery disease.
    Kölbel T; Goncalves I; Dias N; Strandberg K; Acosta S; Gottsäter A
    Thromb Res; 2010 Feb; 125(2):171-7. PubMed ID: 19796792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor.
    Strandberg K; Kjellberg M; Knebel R; Lilja H; Stenflo J
    Thromb Haemost; 2001 Aug; 86(2):604-10. PubMed ID: 11522010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low plasma activated protein C-protein C inhibitor complex concentration is associated with vascular access failure in hemodialysis patients.
    Bakoush O; Ohlin AK; Strandberg K; Kurkus J
    Nephron Clin Pract; 2008; 110(3):c151-7. PubMed ID: 18953177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin-resistant prothrombin Yukuhashi mutation also causes thrombomodulin resistance in fibrinogen clotting but not in protein C activation.
    Takagi Y; Kato I; Ando Y; Nakamura Y; Murata M; Takagi A; Murate T; Kojima T
    Thromb Res; 2014 Oct; 134(4):914-7. PubMed ID: 25149909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.